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Abstract: Elevation of liver enzymes in patients with rheumatoid arthritis treated with 
the biological agents, tocilizumab and anakinra, is now well documented. However, histo-
logical characterization of these effects and outcomes has not been defined. Here we report   
toxic liver effects in two women with rheumatoid arthritis, refractory to all nonbiological thera-
pies, following treatment with anakinra and tocilizumab. Liver biopsy in both cases showed focal 
necrosis of hepatocytes as a hallmark of drug toxicity, along with steatosis and early fibrosis. 
In addition, the patient treated with anakinra demonstrated inflammatory changes. Tocilizumab 
was continued with no further deterioration in liver function. Withdrawal of anakinra led to rapid 
normalization of liver function. The biological agents, tocilizumab and anakinra, may result 
in significant histological hepatic changes, including necrosis, but despite this, the outcome 
appears to be good.
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Introduction
Based on well described efficacy and safety studies, tocilizumab, a recombinant 
humanized anti-interleukin-6 monoclonal antibody, and anakinra, an interleukin-1 
receptor antagonist, have been approved for the treatment of refractory rheumatoid 
arthritis in adults.1–3 Both agents suppress the inflammation and cartilage degrada-
tion associated with rheumatoid arthritis, and both have been reported as safe and 
well tolerated for up to three years of continuous use in patients with the disease.1–4 
Tocilizumab is given intravenously on a monthly schedule and anakinra is given 
subcutaneously once a day.4,5 Common infusion reactions include headache, nausea, 
flu-like symptoms, and local injection site reactions.1,2 The most severe adverse events 
are infections (mainly pneumonia and upper respiratory tract infections), sinusitis, and 
diarrhea.1–4 Sepsis and opportunistic infections, including mycobacterial infection and 
histoplasmosis, have occasionally been reported.1–3 In a large study involving 1346 
patients treated with anakinra or tocilizumab, a total of 15 fatalities occurred during 
a three-year period. These were due to cardiac arrest, myocardial infarction, cerebro-
vascular accident, ventricular fibrillation, sepsis, upper gastrointestinal hemorrhage, 
malignant melanoma, lymphoma, and suicide.1–4
Liver injury in patients treated with tocilizumab and anakinra is now well 
recognized.1–3,6 Increased serum transaminase and bilirubin levels are common, 
requiring dose adjustments or discontinuation.1,7 Liver injury was resolved or alle-
viated in most cases following reduction of the dose of tocilizumab.7,3 In general, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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neither alanine transaminase elevations nor increases in 
bilirubin are associated with clinical evidence of hepatic 
decompensation.1,6,7 Indeed, other etiologies are suspected in 
such cases, including autoimmune hepatitis, steroid-induced 
steatohepatitis, and other drug-induced hepatotoxicity, in 
particular, methotrexate.1,2,7 Although adverse effects of 
anakinra and tocilizumab on the liver have been reported, 
histological evaluation of this pathology has not been 
reported. Here we describe two patients with rheumatoid 
arthritis who developed hepatotoxicity on tocilizumab and 
anakinra. We document the histological changes and their 
good clinical outcomes.
Case report 1
A 46-year-old woman, initially diagnosed as having rheu-
matoid arthritis in May 2000, was treated with methotrexate 
12.5 mg weekly for 10 years. Due to progressive arthralgia and 
severe morning stiffness, despite lack of bony erosions, treat-
ment with methotrexate was discontinued, and tocilizumab 
8 mg/kg (total dose 640 mg) once monthly was instituted 
intravenously in January 2010, with a good clinical response. 
Before administration of tocilizumab, her white blood cell 
count was normal, hemoglobin was 14 g/dL, and platelet count 
was 178,000 mcL. Biochemical data were within the normal 
range, including all liver and renal function tests.
On February 12, 2010, a few days after the second infu-
sion, the patient complained of extreme general weakness and 
fatigue. Laboratory examinations at that time remained within 
normal limits, including liver function tests and hematological 
parameters. Abdominal ultrasound showed mild fatty liver 
and mild splenomegaly. Complete virological, metabolic, and 
autoimmune markers were normal. The patient consumed no 
alcohol and had no other risk factors, including medications 
for liver disease. Due to ongoing severe fatigue, weakness, 
and findings of fatty liver and splenomegaly on initial ultra-
sound, a liver biopsy was performed in July 2010. Histo-
logical examination revealed focal hemorrhagic necrosis of 
hepatocytes, with areas of macrovesicular steatosis (Figure 1). 
Technetium staining showed perisinusoidal fibrosis, with no 
evidence of inflammation or cellular infiltrates. We could not 
find any evidence of hepatitis or other cause of hepatotoxicity 
to explain the findings in this patient.
Case report 2
This case was a 49-year-old woman with a 12-year   history 
of rheumatoid arthritis, and hypertension treated with 
  beta-blockers, and moderate obesity (body mass index 31). 
She had been treated with methotrexate for five years and 
intermittent nonsteroidal anti-inflammatory drugs. She had 
been known to have nonalcoholic fatty liver disease, with 
consistently normal liver function tests. Other than obesity, 
she had no other risk factors for chronic liver disease and was 
taking no other hepatotoxic medications. Due to worsening of 
her rheumatoid symptoms, in particular morning stiffness and 
joint pain, anakinra 100 mg/day subcutaneously was instituted 
in November 2009. Before administration of anakinra, her 
complete blood count and biochemical data, including liver 
function tests, were all within the normal range. Two months 
later, she developed severe fatigue, and laboratory examina-
tion at that time revealed elevated liver function tests, with 
aspartate aminotransferase 30 U/L, alanine aminotransferase 
50 U/L, lactate dehydrogenase 584 U/L, alkaline phosphatase 
161 U/L, gamma glutamyltranspeptidase 85 U/L, and normal 
total bilirubin and amylase. Complete blood count, coagula-
tion profile, and urinalysis remained normal. Full virological, 
autoimmune, and metabolic tests were normal. Ultrasound 
revealed a fatty liver and mild hepatosplenomegaly. Anakinra 
was discontinued, fatigue resolved, and liver function tests 
returned to normal within three weeks.
A liver biopsy (Figure 2) revealed extensive macrovesicu-
lar steatosis (80% of the biopsy volume) with focal necrosis 
of hepatocytes and mild infiltrate of lymphocytes around the 
areas of necrosis and sinusoids of the liver. Technetium stain-
ing showed intraportal fibrosis and perisinusoidal fibrosis. 
These findings were compatible with those of the regression 
phase of acute liver injury.
Discussion
We present here for the first time histological liver changes 
in two female patients due to biological treatment for 
Figure 1 Areas of central hemorrhagic necrosis in the liver.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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  rheumatoid arthritis. The common histological changes 
included focal necrosis with perisinusoidal fibrosis and 
steatosis. Unique to the first patient treated with tocilizumab 
was focal hemorrhagic necrosis without cellular infiltrates. 
The anakinra-treated patient showed steatosis with focal 
necrosis and lymphocytic infiltrates. She had well docu-
mented fatty liver disease, although her liver function tests 
were always within normal limits. It is reasonable to assume 
that development of steatosis was induced by tocilizumab in 
the first patient, and progression from nonalcoholic fatty liver 
disease to nonalcoholic steatohepatitis was due to anakinra 
in the second patient. Interesting to note was that despite the 
remarkable histological findings, the clinical manifestations 
were nonspecific, and the liver enzymes were normal in the 
first case and only slightly elevated in the second case.
Although one patient had an increased body mass 
index and both were exposed to steroid treatment, steato-
sis and   steatohepatitis could also be a manifestation of 
  hepatotoxicity.8 The mechanism by which tocilizumab and 
anakinra is implicated in the pathogenesis of the fatty infil-
trate formation is unclear. Leptin, plasminogen activator 
inhibitor-1, and insulin resistance are suggested to provide 
an etiopathological link.6,9,10,11 However, more studies are 
needed to confirm this complex mechanism.
The liver is unique amongst the body organs in its ability 
to regenerate fully after extensive liver damage.9 Hepatocyte 
activation requires priming by inflammatory cytokines, such 
as interleukin-1, interleukin-6, and tumor necrosis factor 
alpha.7,10,11 Once primed, the hepatocytes respond to a num-
ber of growth factors, including hepatocyte growth factor 
released by stellate cells.6,12 In mice deficient in interleukin-1 
and interleukin-6, regeneration of the liver was suppressed 
after partial hepatectomy.9,8 Therefore, interleukin-6   signaling 
is currently the best characterized pathway thought to be 
  associated with hepatoprotection.10,11
Tocilizumab and anakinra are anti-interleukin-6 and 
anti-interleukin-1 receptors that inhibit interleukin-6 and 
interleukin-1 signal transduction, respectively. The patho-
logical findings suggest acute liver injury.6,12 One strange 
phenomenon was the absence of marked elevation of the 
serum aminotransferase level, suggesting that the hepatocytes 
had gone into apoptosis rather than necrosis or autophagic 
cell death, and that hepatic regeneration had been markedly 
suppressed by blockade of the interleukin-1 and interleukin-6 
pathways.1,6,7,10,11
Conclusion
Here we describe, for the first time, histological changes in 
two cases of acute liver injury due to tocilizumab and anak-
inra, two biological agents commonly used in the treatment 
of rheumatoid arthritis. Drugs targeting interleukin-6 and 
interleukin-1 are being widely used for various other autoim-
mune diseases as well, and could induce severe liver injury 
by promoting apoptosis and inhibiting liver regeneration, as 
in our two cases. Physicians need to be aware of the impact 
of these drugs on the liver.
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